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Alzheimer’s disease is the principal cause of dementia throughout the world and the fourth cause of death in developed
economies.This brain disorder is characterized by the formation of brain protein aggregates, namely, the paired helical ﬁlaments
and senile plaques. Oxidative stress during life, neuroinﬂamamtion, and alterations in neuron-glia interaction patterns have been
also involved in the etiopathogenesis of this disease. In recent years, cumulative evidence has been gained on the involvement of
alteration in neuronal lipoproteins activity, as well as on the role of cholesterol and other lipids in the pathogenesis of this neu-
rodegenerative disorder. In this review, we analyze the links between changes in cholesterol homeostasis, and the changes of lipids
of major importance for neuronal activity and Alheimer’s disease. The investigation on the ﬁne molecular mechanisms underlying
the lipids inﬂuence in the etiopathogenesis of Alzheimer’s disease may shed light into its treatment and medical management.
Copyright © 2006 Leonel Rojo et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Alzheimer’s disease (AD), one of the major types of demen-
tia in the elderly, is characterized by the formation of protein
aggregates in the brain, namely paired helical ﬁlaments com-
posed of hyperphosphorylated tau and senile plaques of the
Aβ amyloid [1]. AD is a multifactorial disease, where four
main factors appear to be involved in its pathogenesis, and
inﬂuence tau pathology: (i) the action of Aβ1−42,A β1−40,a n d
oligomersofthesepeptides[2];(ii)oxidativestressmolecules
[3–5];(iii)proinﬂammatorycytokinesproducedbyactivated
glialcells[6];and(iv)overproductionofNObyglialcells[7].
However, more recently a relevant link between changes in
cholesterol homeostasis and AD has been evidenced [8–10].
The diﬀerent factors triggering the degeneration of neu-
rons modify various signalling pathways. Their actions ap-
pear to be mediated by the activation of the protein ki-
nase systems cdk5/p35 and GSK3β, with the consequent hy-
perphosphorylation on tau [11]. The mechanisms involv-
ing the sequence of events after the neuronal insult by these
molecules have been analyzed using as biological models ei-
ther cell lines, primary cultured hippocampal cells, or trans-
genic mice models, such as Tg2576 [12] which expresses the
Swedish mutation of the amyloid precursor protein APP, and
other transgenic models of tau protein [13]. Aβ peptides and
their oligomers induce alterations in the signalling cascades
via activation of glial cells, or directly in neurons. Oxidative
stress appears to be an early event in AD pathogenesis. The
equilibrium between phosphatases and protein kinase activi-
tiesisaltered,andtauhyperphosphorylationsoccurasacon-
sequence of deregulation in the cdk5 and MAP kinases sig-
nalling cascades [3]. These studies are consistent with some
clinical ﬁndings in which cognitive decline in mild cognitive
impairment (MCI) and AD patients, analyzed by neuropsy-
chological tests, correlated with the levels of hyperphospho-
rylated tau markers in the cerebrospinal ﬂuid [14, 15]. More-
over,thesestudiesarerelevanttotheelucidationofthemech-
anisms involved in the etiopathogenesis of AD, and provide
clues toward novel diagnostic approaches for this disease.
L e ee ta l[ 16] have provided evidence that points to al-
terations in rafts physiology in amyloid processing, a phe-
nomenon, which appears to be modiﬁed by changes in
cholesterol content in “lipid rafts,” suggesting a direct link
between cholesterol and AD. On the other hand, tau protein
has also been found in rafts, and tau modiﬁcations by the Src
kinase Fyn have been reported [16]. Fyn is present in rafts,2 Journal of Biomedicine and Biotechnology
microdomains composed of cholesterol, and sphingolipids
that participate in signal transduction systems. In addition,
tau phosphorylation by Src kinases such as Fyn seems to be
overactive in AD.
ETIOPATHOGENESIS OF ALZHEIMER’S DISEASE
Neuropathologically, AD has been characterized by extensive
degeneration of cholinergic projection neurons of the basal
forebrain nucleus basalis (NB), the presence of extracellu-
lar neuritic plaques mainly constituted by amyloid β-peptide
(Aβ), intracellular deposits of neuroﬁbrillary tangles formed
bypairedhelicalﬁlaments(PHFs)containingthehyperphos-
phorylated tau protein, microglial-mediated inﬂammatory
reaction, and neuronal death [1, 17, 18]. Even though, the
pathogenic process leading to AD development has not been
clearlydeﬁned;molecularandgeneticfactorsareinvolved.In
this review we emphasize the involvement of lipids compo-
nents among the biochemical risk factors for AD.
GeneticfactorsandthefamilialAD
Among the genetic causes of AD, mutations and polymor-
phisms stand out in at least four genes. Mutations are as-
sociated with early-onset familial AD (EOAD) that account
for 3% of all cases of AD and usually occur between the
age of 30 and 60. These are diﬀerent than the sporadic AD
cases (more than 97%), even though genetic succeptibility
and other molecular risk factors appear to be also involved.
Alzheimer disease type 1 (AD1) is linked to mutations in
the amyloid precursor gene (APP) [19]; while AD3 is caused
by a mutation in the gene of presenilin-1 (PSEN1), located
in chromosome 14 that encodes for a 7-transmembrane do-
main protein [20]; whereas AD4 accounts for mutations in
the gene of presenilin-2 (PSEN2) on chromosome 1 [21]
that encodes a similar 7-transmembrane domain protein.
On the other hand, the late-onset of familial AD after age
65 is correlated with mutations AD2, related to the APOE4
allele on chromosome 19 [22], while AD7 and AD8 cor-
respond to mutations that have been mapped to chromo-
somes 10p, 13p, and 20p, respectively [23, 24]. Mitochon-
drial DNA polymorphisms are also considered as a genetic
risk factor [25, 26]. Furthermore, there is an association be-
tween a polymorphism in alpha-2 macroglobulin with low
densitylipoprotein-relatedprotein-1(LRP1),whichisthere-
ceptor for A2M; and with APOE and APP [27, 28]. These
studies suggest the possibility that all these proteins, A2M,
LRP1, APOE, and APP, may participate in a common neu-
ropathogenic pathway contributing to AD-related neurode-
generation.
Importantlinksbetweenthemainbiochemical
eventsinAD
One of the hallmarks of AD is the observation of neuroﬁb-
rillary tangles (NFT), intracellular ﬁlamentous aggregates of
the microtubule-associated protein tau. Physiologic func-
tions of tau stem from its ability to stabilize microtubules
during axonal transport and its capability to help in the neu-
rite growth [29]. Tau is regulated by phosphorylation. In a
hyperphosphorylated status, tau detaches from the micro-
tubules and, consequently, the microtubules fall apart and
tau tends to aggregate in paired helical ﬁlaments (PHF), thus
inducing breaks in the microtubular tracks and neuronal
death[30].Speciﬁcsitesappeartobepreferentiallyphospho-
rylated early in patients with AD, as, for example, the KXGS
motifs targeted by the enzyme MARK, a serine-threonine ki-
nase important for maintaining a polar network of micro-
tubules, and, thus, cell polarity in neurons [31]. In addition
totheintracellularNFT,theextracellularlesionsaretheamy-
loid plaques (or senile plaques) produced by the accumula-
tion of amyloid (Aβ) beta peptides. Once cell-bound beta-
amyloidprecursorprotein(APP)iscleavedbytheβ-secretase
(BACE), it generates a soluble ectodomain sAPPβ and a C-
terminal fragment CTFb, that is subsequently cleaved by γ-
secretase originating neurotoxic soluble Aβ peptides that ag-
gregate in oligomers to form these ﬁbrillar structures [32].
APP interacts with multiple components of the nervous sys-
tem mediating functions that include neuronal trophism,
cell adhesion, neuronal migration, neurite outgrowth, cell-
cell signalling, synapse formation, and plasticity. The active
movement of APP within neurons contributes to transcrip-
tion in the nucleus and apoptosis in the cytoplasm. Another
cleavage of APP at the ε-site results in a fragment that can be
stabilized by interaction with the factor Fe65. APP, Fe65, and
Tip60 form a transcriptionally active complex that partici-
pates in gene transcription, thus making APP a gene regula-
tor. However, a regulatory mechanism should exist to mod-
ulate APP levels since an excess of APP may lead to APP
oligomerization, caspase activation, and neuronal apoptosis
[33].
Oxidative damage and mitochondrial DNA alterations
are involved in the neurodegeneration associated with AD.
In AD, brain mitochondrial DNA point mutations have been
foundtoappearspeciﬁctothiscondition.Someofthesewere
associated with defects in oxidative phosphorylation. Addi-
tionally, the incidence of mitochondrial DNA mutations has
been found to increase by 50% in AD patients [34, 35]. The
mechanism that links mitochondrial alterations with neu-
rodegeneration, as well as aging, is related to the oxidative
and molecular damages that are being inﬂicted over time.
Also, the oxygen-reactive species (ORS) scavenging mecha-
nisms deteriorate with age and can be associated to func-
tional deﬁcits [36].
Even though, the earlymolecularevents thatoccur in AD
are not clear, the synapse loss is considered to be one of the
morphological correlates related to the impairment of cog-
nitive function observed in mid to late stages of AD [37]. It
has been postulated that synaptic dysfunction precedes this
synapse loss in AD [32]. In this regard, changes in the lev-
els of proteins involved in synaptic vesicle biogenesis and/or
recycling have been reported, like SNAP-25, syntaxin, and
synaptotagmin in AD [38]. A second example is the critical
reduction in the levels of dynamin 1 observed in AD brains,
an essential protein in synaptic vesicle recycling [39]. This
reduction is attributed to Aβ since it has been shown thatLeonel Rojo et al 3
Aβ decrease the dynamin 1 levels involving calpain-mediated
proteolysis and down-regulation of dynamin-1 gene expres-
sion [40].
Generalriskfactorsandthechangesinlipidsas
ariskfactor
Epidemiologic studies have evidenced several risk factors for
AD. Age represents one of the stronger risk factors for AD
[41]. The prevalence of AD doubles every 5 years after the
age of 60, increasing from a prevalence of 2% among those
60- to 64-year-old to up to 50% of those aged 85 years and
older [42]. Studies have shown that AD is more common
among women than men by a ratio of 1.2t o1 .5[ 43]. An-
other important risk factor is the presence of the apolipopro-
tein e-4 (APOE epsilon-4) allele [44]. Of its three forms,
ε-2, -3, and 4, only the ε-4 allele increases the likelihood
of developing AD. The lifetime risk of AD for an individ-
ual without the ε-4 allele is approximately 9%; the lifetime
risk of AD for an individual carrying at least 1 e-4 allele
is 29%. While representing a substantial risk of AD, the
ε4/ε4 genotype is not suﬃciently speciﬁc or sensitive to al-
low its use as a diagnostic test. Moreover, ε-4 allele appears
to increase the risk of AD more in white and Asian pop-
ulations than in black and Hispanic populations [45, 46].
Additionally, hypertension [47, 48], heart disease [49], obe-
sity at midlife [50], smoking [51], elevated plasma homocys-
teine levels [52], diabetes [53, 54], as well as hypercholes-
terolemia [55, 56] are also considered as risk factors for
AD.
In relation to hypercholesterolemia, several reports have
shown that elevated serum cholesterol levels and elevated
levels of Aß are linked with AD risk [57, 58]. Addition-
ally a cluster of polymorphisms in cholesterol-related genes
such as APOE, SOAT1, APOE 5 -untranslated region, OLR1,
CYP46A1, LPL, LIPA, and APOA4 has been shown to cor-
relate with levels of the brain cholesterol catabolite 24S-
hydroxycholesterol in the cerebrospinal ﬂuid conferring sig-
niﬁcantsusceptibilitytoAD[59].Studiesusingstatins,lipid-
lowering agents that inhibit HMG-CoA reductase: the key
enzyme of the endogenous cholesterol synthesis, indicate
that statins also can aﬀect γ-secretase activity, thereby de-
creasing the breakdown of APP and reducing the risk of
AD [60, 61]. Consequently, the proteolytic activity of γ-
secretase is stimulated by neutral glycosphingolipids (cere-
brosides), anionic glycerophospholipids, and sterols (choles-
terol), showing the involvement of lipids and rafts in the
modulation of BACE activity [62]. Furthermore statins
exhibiting anti-inﬂammatory actions [63, 64]h a v eb e e n
able to down-regulate the Aβ-mediated inﬂammatory re-
sponse independent of cholesterol reduction [65]. These
anti-inﬂammatory eﬀects involve the functional inactiva-
tion of members of the Rho subfamily of small G-proteins,
which regulate the actin-based cytoskeleton and participate
in proinﬂammatory signalling pathways inducing cytokines
and chemokines. This inactivation occurs through a mech-
anism that blocks the isoprenylation, a lipid modiﬁcation
of Rho-family members that facilitates speciﬁc interactions
with cytoplasmic regulators, cellular membranes, and eﬀec-
tors [66, 67]. Recent ﬁndings demonstrate that the anti-
inﬂammatory action of statins depends on the disruption
of Rho family functions, as a consequence of reduction of
isoprenoid cellular levels, preventing Rho family members
from interacting with RhoGDI, resulting in increased levels
of GTP-loaded G-proteins and reducing the Rac transloca-
tion to the plasma membrane [68]. In this context, Rac1 sig-
nalling as well as the enzyme BACE1 have been postulated
as targets for developing novel therapies for AD [69]. These
observations underlie a mechanism for the statin-mediated
reduction in AD risk that involves down-regulation of neu-
ronal APP processing and Aβ production and attenuation of
microglia-mediated inﬂammation.
REGULATION OF TAU PROTEIN AND ITS POST-
TRANSLATIONAL MODIFICATIONS
Since modiﬁed tau variants have been found in membrane
domains, their interactions with lipids and the involvement
of these molecules in AD are analyzed below. Tau is pro-
duced from a single gene in the chromosome 17 by alter-
native splicing, mainly during neuronal development [74].
The splicing products are 6 isoforms that diﬀer in molecu-
larweightaccordingtothenumberofN-terminalrepetitions
andthenumberofmicrotubulebindingsequencesattheirC-
terminal domains [75]. The expression of tau isoforms also
diﬀers in central and peripheral nervous system and depends
on the developmental stage. In rat brain tau starts its ex-
pression at the embryonic day 13, only the shortest isoform.
From the postnatal day 8, this fetal tau isoform decreases,
andthenewisoforms,called“adultforms,”starttheirexpres-
sion. In the adult peripheral nervous system, there is another
kind of tau, the high molecular weight isoform (110kDa),
which contains two additional expressed exons. In general,
tau is a highly soluble protein, with a majority of hydrophilic
residues; these characteristics mean that tau is a protein that
has a natively unfolded structure, that confers resistance to
heat and acid treatments.
Tau can be regulated post-translationally by phosphory-
lations, ubiquitinations, and O-glycosylations. This last con-
sists of the addition of an O-linked N-acetylglucosamine (O-
GlcNAc) on a Ser or Thr residues in the proximity of a Pro.
Tau phosphorylation appears to be especially relevant con-
sidering that anomalous phosphorylations are involved in
AD. The equilibrium between the protein kinases and phos-
phatases regulates the existence of these phosphorylations
(Table 1).
TauphosphorylationsatSer/Thrresidues
Two diﬀerent Serine-Threonine kinases have been described.
(i) Proline-directed protein kinases that recognize consen-
sus sequences that are followed by prolines. This group in-
volves glycogen synthase kinase 3 (GSK3), cdk2 and cdk5;
mitogen-activated protein kinases MAPK family, Erk1 and
Erk2; and the stress-activated protein kinases (SAPK), JNK
and p38 [11, 76]. These enzymes aﬀect tau self-aggregation4 Journal of Biomedicine and Biotechnology
Table 1: Summary of the diﬀerent protein kinases implicated in Tau phosphorylation, the exact residues that are modiﬁed by them and
the phosphatases that participate in the dephosphorylation process of each residue. Phosphatases are (1) PP1, (2) PP2A, and (3) PP2B. See
[70–73].
Kinase Phosphatase
2,3 2 2,3 1,2,3 1,2,3 2,3 3 3 1,3 3 1,2,3 1,2,3 3
PKA — — — — — — — — S214 — T234 S262 T293 S324 S356 — S404 S409 S416
PKB — — — — — — — T212 S214 — — — — — — — — — —
PKC — T123 — — — — — — — — — — — — — S396 S404 — S416
CaMKII — — — — — — — — — — — S262 — — S356 — — — S416
p110mapk — — — — — — — — — — — S262 — — — — — — —
JNK — — T175 T181 — S202 T205 T212 — — — S262 — — — S396 S404 — —
p38 S46 — T175 T181 — S202 T205 T212 — — — — — — S356 S396 S404 — —
SAPK3 — — — T181 — — — — — — — S262 — — S356 — — — —
ERK2 S46 — T175 T181 — S202 T205 T212 — — — — — — — S396 S404 — —
GSK3β — — T175 T181 S199 — — T212 — T231 — — — — — S396 S404 — —
Cdk5 — — — T181 — S202 T205 T212 T231 — — — — — S396 S404 — —
Cdk2 S 4 6 ——— — — —————————— ———
and phosphorylations occurring in the N-terminal and in
the C-terminal tau moieties. (ii) Nonproline-directed pro-
tein kinases that recognize consensus sequences that are not
followed by prolines. These include protein kinase C (PKC),
protein kinase A (PKA), Ca+2/calmodulin-dependent kinase
II(CaMkinaseII),Ser262kinase/p100mapk,andmicrotubule
aﬃnity regulating kinase (MARK). These phosphorylations
mainly occur at the tubulin-binding region of tau [77, 78].
Nonproline-directed serine-threonine phosphorylations
of tau aﬀect the microtubule aﬃnity. Ser262/Ser356 sites,
in the repeat domain of tau, are critical for tau binding
to microtubules; therefore, when tau is phosphorylated in
these residues, its aﬃnity for microtubules diminishes. Tau
phosphorylation status at these Ser residues plays a key
role in the extension of cell processes [79]. Since tau sta-
bilizes microtubules when it is bound to them, and neu-
rites extension process needs the elongation of microtubules,
then phosphorylations in Ser262 and Ser356 render micro-
tubules less stable. Proline-directed serine-threonine phos-
phorylation of tau comprises almost 80% of total tau phos-
phorylation; it has a weak eﬀect on microtubule bind-
ing and is regulated during neuronal development. This
p h o s p h o r y l a t i o ni se n h a n c e di nA D .I th a sb e e no b s e r v e d
[79, 80] that the decrease in Ser/Thr-Pro phosphoryla-
tions favors the extension of processes, that is, when these
sites are dephosphorylated. Phosphorylations are done by
proline-directed protein kinases and mainly occur on the
C-terminal region, thus modifying tau aﬃnity for micro-
tubules [78–80]. An imbalance in kinases triggers tau hy-
perphosphorylation, producing the paired helical ﬁlaments
(PHFs), the basic components of neuroﬁbrillary tangles
(NFTs) [81].
PhosphorylationsatTyrresidues
Tau can associate cell plasma membrane by its N-terminal
region [82] without altering its microtubules binding. Tau
can be phosphorylated by Fyn, a tyrosine kinase from the
nonreceptor Src family kinases [83]. Fyn participates in the
signal transduction system related to integrins having re-
sponses such as the Ras and Rho activations and the conse-
quent actin reordering [84]. Bhaskar et al [85] have shown
that Src also phosphorylate tau in Tyr 18 in vitro. In ad-
dition, Derkinderen et al [86] demonstrated that Abl phos-
phorylates tau in Tyr 394; both phosphorylations are present
in PHFs. Tyr 18 is conserved in all tau isoforms and the se-
quencearoundthisresidue(GTYG)isclosetothebindingse-
quence of Fyn to its target (ETYG). Among the 7 PXXP mo-
tifsoftau,onehasthemajoraﬃnitytoFynSH3domain[84].
Moreover, Fyn has more aﬃnity for 3R tau than for 4R tau,
however, the low aﬃnity for 4R tau is considerably increased
by phosphorylations present in AD-like Ser 199/Ser202 and
Ser 396/Ser 404, epitopes recognized by AT8 and PHF1 an-
tibodies [85]. Since tau 3R plays an important role in neu-
ronal development, its aﬃnity with Fyn has a major function
in this process. Meanwhile, tau 4R is mainly present in adult
brain, and the increase in its aﬃnity for Fyn may have an im-
portant eﬀect in AD etiopthogenesis (Figure 1).
TAU PROTEIN IN PLASMA MEMBRANE
In the context of the involvement of lipids in AD, membrane
tau appears to be relevant. The C-terminal tau domain is
related to the binding of microtubules and actin ﬁlaments,
participates in the stabilization of the cytoskeleton, and is aLeonel Rojo et al 5
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target for phosphorylations in Ser/Thr residues that regulate
microtubule binding and the aggregation of tau in neurolog-
ical diseases. The N-terminal moiety, is a projection of the
protein and does not participate in the stabilization of mi-
crotubules and extension of neurites, as shown in deletion
experiments [87, 88]. Brandt and Lee [87] showed that the
projection domain is present in the plasma membrane of
transfected PC12 cells with tau and its N-terminal domain.
In nonneuronal models such as rat ﬁbroblast (RAT-1), tau
was not enriched in the periphery of the cell, indicating that
its membrane localization requires the presence of neural-
speciﬁc factors [87].
The association of tau to the plasma membrane is deter-
mined by its phosphorylation patterns [82]. Tau-1 antigens
were detected in the membrane (tau dephosphorylated in
Ser 199). When tau phosphorylation increases, it dissociates
frommembranes.Thus,tauphosphorylationstatusregulates
its capability to bind to microtubules. Then, the pathologi-
cal hyperphosphorylation of tau could lead migration of the
subpopulation of tau associated to the plasma membrane to
the cytosol, triggering its binding to microtubules or its ag-
gregation. This is consistent with the lesser amount of tau
phosphorylated at PHF1 and AT8 epitopes in the plasma
membranes in AD [82].
It has been proposed that tau binds the plasma mem-
brane in association with the membrane cortex, that is, the
actin cytoskeleton present in the periphery of the cell [82].
Tau binds actin by the same amino acids used for the mi-
crotubule binding [88], and is regulated by the phosphoryla-
tion status. The accumulation of tau in the somatodendritic
compartment produced in AD could be triggered by a loss of
tau-cortical interaction as a result of the phosphorylation in
PHF-like epitopes.
The phosphorylation pattern of tau is aﬀected by phos-
pholipids [89]: incubation of tau with phosphatidyl serine
(PS), and MAP kinases showed that the phosphorylation of
tau in PHF epitopes decreased, increasing the Tau1 reactiv-
ity. Phosphatidyl choline (PC) showed the same results, but
phosphatidylinositol(PI)didnot.PSalsoreducedthecosed-
imentation of tau with microtubules in experiments of tau-
tubulin association and enhanced the tau proteolysis by cal-
pain.Thelipidcomponentsoftheplasmamembraneareable
by this way to alter tau function, making the tau subpopula-
t i o np r e s e n ti nt h i sc o m p a r t m e n t ,d i ﬀerent from the cytoso-
lic tau.
In rafts, the exoplasmic leaﬂet is enriched with sph-
ingomyelin and glycosphingolipids, the cytoplasmic leaﬂet
is enriched with glycerolipids (phosphatidyl serine and
phosphatidyl ethanolamine). Cholesterol is present in both
leaﬂets. Some proteins such as those with GPI anchors are
alsopresentinrafts,leavingtheGPIintheexoplasmicleaﬂet;
also present in rafts are proteins with transmembrane do-
mains, like the inﬂuenza virus proteins and haemaglutinin
(HA) [90] and the palmitoylated such as Src family kinases.
Thehydrogen-bondingpropertiesofglycosphingolipidswith
themselves and with the GPI anchor the GPI-linked proteins
to stabilize the complexes formed in the microdomains. In
addition,cholesterolhasaplanarshapethatfavorsitsorgani-
zation in the membrane, also giving stabilization. The lipids
can move in and out of rafts individually, making this system
highly dynamic.
In oligodendrocytes, the myelination process is led in
great part by Fyn. Fyn knockout mice lack correct myeli-
nation. Fyn interacts with tau, and tau interacts with mi-
crotubules. Both are present in the rafts in the oligodendro-
c y t e s( s e e[ 91]), forming a complex as evidenced by tau-Fyn6 Journal of Biomedicine and Biotechnology
coimmunoprecipitation in raft and nonraft fractions. It was
alsoobservedthattubuliniscapableofbindingSH2andSH3
domains of Fyn, whereas tau only binds the SH3 domain.
WhenthecellsweretransfectedwiththeN-terminaltaumoi-
ety containing the PXXP motif that interacts with Fyn, the
number and length of processes diminished because tau N-
terminal competes for the Fyn binding. Klein et al [91]p r o -
posedamodelinwhichFyninteractswithtauinrafts,andin
turn tau interacts with microtubules allowing the extension
process of oligodendrocytes when these cells contact neigh-
bor neurons.
POTENTIAL ROLE OF LIPIDS AND CHOLESTEROL IN AD
Membrane lipids are essential for biological functions rang-
ingfromprocessesinvolvingtraﬃckingofmoleculesandsig-
nalling transduction. Lipids and cholesterol are transported
through the blood stream by lipid-protein particles, lipopro-
teins that can be classiﬁed in diﬀerent subsets according ot
their density: high density (HDL), medium density (IDL),
low density (LDL), and very low density (VLDL). LDL has
an elevated fat proportion and participates in lipids trans-
ported from blood stream to peripheral tissues. HDL has a
majorproteinfractionwithrespecttolipids,andtakespartin
reverse cholesterol transport from peripheral tissues to liver
where conjugation and excretion occur. Cholesterol is trans-
ported in the plasma predominantly as cholesteryl-esters as-
sociated with lipoproteins. Cholesterol derived from diet is
transported from the intestines to the liver within chylomi-
crons. Cholesterol can be synthesized de novo by the liver
using acetyl-CoA as precursor molecule. In this biochemical
pathway, the enzyme HMG-CoA reductase has a main role
in the pharmacological intervention to diminish the endoge-
nous cholesterol synthesis. Finally, cholesterol is excreted in
thebileasfreecholesterolorasbilesaltsfollowingconversion
to bile acids in the liver [92].
Brain cholesterol is mainly synthesized locally within the
CNS. It is estimated that during CNS development, neurons
synthesize most of the cholesterol needed for their growth
and synaptogenesis. Later, when neurons are mature, they
reduce their endogenous cholesterol’s synthesis and become
more dependent on cholesterol synthesized and secreted by
the astrocytes [93] .C h o l e s t e r o li nt h eC N Si st u r n e do v e ri n
ap r o p o r t i o no f0 .7% of the total amount every day. Even
though,itisnotagreatfraction,itisarelativelyhighamount
of cholesterol considering that the CNS accounts for 2.1% of
body weightandcontains23%ofthetotalsterolinthewhole
body.Thebrainisthereforethemostcholesterol-richhuman
organ. In addition, cholesterol accounts for 20–25% of the
totallipidsinneuronsplasmamembranes.Thus,neuronsre-
quire a continuous supply of new cholesterol to maintain its
constant concentration in the plasma membranes. Eukary-
oticcellsincorporatecholesterolthroughatleastthreemech-
anisms: (1) de novo synthesis within the cell from acetyl-
CoA, which is the most important mechanism for neurons,
(2) uptake of unesteriﬁed or esteriﬁed cholesterol from the
external environment using the LDL receptors (LDLR), or
(3) the Niemann-Pick C1-like protein (NPC1L1) (90).
LDLR bind particles that contain either apoE or ApoB-
100 (remnants of chylomicrons, very low density lipopro-
teins (VLDL), and LDL) [94]. These particles are then pro-
cessed through the clathrin-coated pit pathway to late endo-
somes and lysosomes. Then, the hydrolysis of the cholesteryl
esters takes place and cholesterol becomes part of the
metabolically active pool within the cell. At this ﬁnal stage,
cholesterol performs a variety of functions: it can be trans-
ferred to the plasma membrane, metabolized to other prod-
ucts, or act as a regulator of cell sterol metabolism [94]. Two
other proteins; Niemann-Pick type C1 and C2 (NPC1 and
NPC2), are also required to move the unesteriﬁed choles-
terol to the metabolically active pool. However, their roles
remain uncertain so far [92]. Current evidence indicates that
cells with dysfunctional NPC1 or NPC2 accumulate unester-
i ﬁ e dc h o l e s t e r o li nl a t ee n d o s o m e s ,w h i c hr e ﬂ e c t saf a i l u r eo f
cholesterol to exit eﬃciently this compartment and travel to
the plasma membrane and endoplasmic reticulum [95]. This
failure of cholesterol traﬃcking can be explained, in part, by
its genetic basis, which involves mutations of either of two
functionally related genes, NPC1 and NPC2, accounting, re-
spectively, for 95% and 5% of the cases [95].
Cholesterol cannot pass directly through the blood-
brain barrier (BBB). Firstly, it has to be oxidized into
27-hydroxycholesterol and/or 24S-hydroxycholesterol in the
peripheral organs or in the CNS, respectively. As 24S-
hydroxycholesterol is synthesized in the brain and spinal
cord, concentrations of this late metabolite are higher in the
CNS than in any other tissue. Some authors have even sug-
gested that 24S-hydroxycholesterol peripheral levels can be
used as a marker for AD [96]. In fact, during the early stages
of AD, 24S-hydroxycholesterol levels are high in CSF and
in peripheral circulation, even though the physiological ex-
planation for this fact and its implications for AD are still
unknown [96, 97]. The transport of excess cholesterol out
of cells is mediated by ABCA1, a membrane protein that
facilitates the formation of APOE-cholesterol-phospholipid
(ApoE-Chol-PL) complex and requires the hydrolysis of ATP
for its activity. Upon secretion of the APOE-Chol-PL com-
plex into the extracellular environment, the complex may
bind to LDL receptor-related protein (LDLRP) to be taken
up by neurons or form HDL-like particles for transport to
the systemic circulation [93].
Cholesterol inﬂuences the activity of the enzymes in-
volved in the metabolism of the amyloid precursor protein
and in the production of Aβ [58]. In some animal studies,
dietary cholesterol accelerated Aβ deposition in the brain,
whereas cholesterol-lowering drugs lowered it [58–60]. Also,
in other in vivo studies a lower-cholesterol environment re-
sulted in an increased production of soluble amyloid precur-
sor protein [98]. Themechanism bywhichcholesterol aﬀects
Aβproductionandmetabolismisnotfullyunderstood.Ithas
been suggested that possible mechanisms related to changes
in plasma membrane stiﬀness and ﬂuidity could explain the
inﬂuence of cholesterol on enzymes like BACE 1. The high
cholesterol content in lipid rafts, where these enzymes are
located, could facilitate the clustering of α and β secretases
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promoting the undesirable pathogenetic cleavage of amy-
loid precursor protein [58, 69]. This suggests that the use
of statins might decrease the levels of cholesterol in neu-
rons thereby altering the organization of lipids rafts. How-
ever, Abad-Rodriguez et al have demonstrated that some of
the most commonly used statins are poor penetrators of the
blood-brain barrier [99], so their beneﬁts in the prevention
of AD development might derive from anti-inﬂammatory or
antioxidant properties rather than a direct eﬀect on choles-
terol concentration in the plasma membrane of neurons.
In neuronal and glial membranes, cholesterol is distributed
asymmetrically among the two membrane leaﬂets. In nor-
mal physiological conditions, the plasma membrane cytofa-
cial leaﬂet contains more than 85% of the membrane choles-
terol in the synaptic plasma membrane, whereas the choles-
terol content of the exofacial leaﬂet is low [93]. Some statins
may raise this ratio by lowering the cholesterol content of the
exofacial leaﬂet [100]. However, these eﬀects of statins in the
brain vary depending on the lipophilicity of each molecule.
This suggests that, rather than reducing brain cholesterol, a
feasible explanation for the eﬀect of statins might be that
they alter the cholesterol balance in the plasma membranes
of brain neurons. However, the signiﬁcance of these eﬀects
on the human brain is still unknown.
In vivo experiments have shown that there are diﬀer-
ences between the eﬀects of simvastatin, a lipophilic statin;
and pravastatin, a hydrophilic statin, when given as a high-
dose short-term treatment [70]. Simvastatin reduced the lev-
els of lathosterol, a cholesterol precursor, but did not af-
fect the formation of 24(S)-hydroxycholesterol. The HMG-
CoA reductase and ABCA1 mRNA expression in the brain
was signiﬁcantly upregulated in animals treated with sim-
vastatin compared to those treated with pravastatin or with
placebo. These ﬁndings suggest that cholesterol synthesis
is signiﬁcantly aﬀected by short-term treatment with high
doses of lipophilic simvastatin, while whole brain cholesterol
turnover is not disturbed [70].
Altogether, there is still no evidence for the net transfer
of sterol from the systemic circulation into the brain. De-
tails about the implications of cholesterol blood levels in the
development of AD are therefore an open ﬁeld for research.
Niemann-Pick type-C disease (NPC) is a juvenile, fatal au-
tosomal recessive neurovisceral lipid storage disorder. NPC
is associated with a progressive neurodegeneration, thereby
resulting in dementia caused by dysfunction of the neuronal
network[101].HallmarksofNPCareballoonedneuronsand
massive neuronal loss with massive intracellular cholesterol
accumulations both in human and in murine NPC brain
[102].
Although NPC diﬀers in major respects from AD, in-
triguing parallels exist in the cellular pathology of these two
diseases, including neuroﬁbrillary tangle formation, promi-
nent lysosome system dysfunction, and inﬂuences of the
apolipoprotein E4 genotype. In addition, accumulation of
cleaved APP and Aβ peptides within endosomes has been
observed in NPC [95]. In vivo experiments using murine
models of NPC have demonstrated that tau protein is phos-
phorylated at epitopes considered to represent early stages
of AD [102]. This strengthens the concept that an alteration
in cholesterol metabolism could play a pivotal role in early
stages of AD.
CHOLESTEROL IN LIPID MEMBRANE MICRODOMAINS
(RAFTS) AS AN APPROACH TO STUDY
ALZHEIMER’S DISEASE
Several protein systems use lipid rafts as a platform for
signalling. “Lipid raft” is basically a deﬁnition given to
those membrane domains rich in cholesterol and glycosph-
ingolipids isolated from cells or cell membranes prepara-
tions through detergent and nondetergent methods [71].
Names like cholesterol enriched membranes (CEMs), gly-
cosphingolipid enriched membranes (GEMs), detergent-
insoluble, glycosphingolipid-enriched membranes (DIGs),
and detergent-resistant membranes (DRMs) have been given
to these rigid plasma membrane fragments based on their
preferential lipid composition and/or nonionic detergent re-
sistance properties [103]. Rafts can be invaginated or not de-
pending on whether they are composed of a protein called
caveolin. This protein interacts with the membrane making
a hairpin loop and raising caveolae; these are considered as
specialized forms of rafts implicated in cell transduction.
During the last ten years, numerous data obtained from
a wide variety of biophysical and biological techniques
have helped to explain the composition and function of
lipid rafts. However, there are still many unanswered ques-
tions, especially in the area of cholesterol/lipids and choles-
terol/proteins biochemical interactions and diﬀerential seg-
regation.Inthelightofcurrentlyavailablescientiﬁcevidence,
it seems clear that lipid rafts composition strongly depends
on the “isolation” method used to obtain them [72, 104].
A plausible hypothesis to explain the diﬀerences occurring
in cholesterol, glycosphingolipids, and proteins composition
of lipid rafts, based on diﬀerent isolation methods, has been
recently described. In this hypothesis, scientiﬁc evidence is
presented and discussed in order to support the existence
of three diﬀerent models of raft structure based on the uti-
lization of diﬀerent raft isolation protocols. The ﬁrst two
predict that all rafts isolated by the same method will have
similar composition and the third predicts that rafts iso-
lated by the same method could be heterogeneous in com-
position because the domains themselves are heterogeneous
[105]. Conversely, Rajendran et al showed that, in lympho-
cytes, raft proteins like lck, lyn, and LAT were released from
lipid rafts by treatment with methyl-β-cyclodextrin; whereas
ﬂotilinsmarkersremainedindetergentresistantmembranes,
suggesting that some rafts require less cholesterol than oth-
ers to maintain their integrity, or that some rafts retain their
cholesterol more eﬀectively than the others by cholesterol se-
questering agents [73].
It seems, therefore, of pivotal importance to focus on
the raft isolation methods when discussing cholesterol rafts
and their possible role in any pathophysiological event. Al-
together, despite the heterogeneous composition found in8 Journal of Biomedicine and Biotechnology
lipid rafts, it is widely accepted that they are membrane do-
mains rich in cholesterol and glycosphingolipids [106, 107].
Lipid composition is approximately 1 : 1 : 1, phosphoglyc-
erolipids: sphingolipids (including sphingomielin (SM) and
glycosphingolipids (GSL)): cholesterol. In rafts isolated us-
ing detergent protocols, the phospholipid population is en-
riched in saturated acyl chains relative to the average for
whole cell phospholipids [108]. Conversely, little consistent
evidencehasbeenprovidedregardingthemechanismunder-
lying cholesterol selective migration, residence, and dynam-
ics in these membrane lipid rafts.
Ipsen et al have proposed a lipid membrane spatial dis-
tribution theory that partially helped to explain the clus-
tering of lipids into the cholesterol rich domains; they pro-
posed that cholesterol and phospholipids form a liquid-
ordered (Lo) phase characterized by a high level of molec-
ular order in the lipid packaging [109]. According to this
hypothesis, the Lo phase would coexist with the liquid-
disordered phase (Ld) or liquid-crystalline phase, charac-
terized by a high degree of disorder and very high lipid
mobility, and with the gel phase, in which lipid molecules
are virtually immobile. Lipids and proteins that “prefer”
liquid-orderedphase(includingbothglycosphingolipidsand
glycosylphosphatidylinositol-anchored proteins) would seg-
regate into the Lo-phase domains and thus into lipid rafts.
However, this hypothesis appears to be controversial since,
according to Brown [110], it does not have enough support.
Importantly, a signiﬁcantly lower ﬂuidity was found in acyl
chainofcaveolae/raftdomainswhenpuriﬁedwithouttheuse
of detergents [103].
In spite of its limitations, giant unilamellar vesicles
(GUVs), an artiﬁcial membrane system, have provided a
very useful tool to elucidate the biophysical mechanisms of
raft assembly, especially allowing for the study of choles-
terol and lipids dynamics in a noninvasive manner [111].
Application of FCS combined with confocal scanning mi-
croscopy allows for the determination of single molecule dif-
fusion, chemical kinetics, and conformational equilibrium.
Thus, it has become a valuable insight into lipid/cholesterol
interactions and lipid dynamic organization during lipid
rafts assembly [111, 112]. By applying these techniques, Ka-
haya et al [112–114] have established that both dioleoyl-
phosphatidylcholine (DOPC) and DLPC, unsaturated phos-
pholipids, gradually decrease their mobility as a func-
tion of cholesterol concentration [113]. When compared
to DOPC, bigger changes in mobility were exhibited by
DLPC, meaning that cholesterol would interact more inti-
mately with the saturated phospholipids. They found that
cholesterol interacts more strongly with SM than phos-
phatidylcholine (PC), implying that the latter interaction
may have a role in the stiﬀness of SM membranes with
respect to PC bilayers. In addition, in ternary mixtures, a
weakertendencytoformextensivedomainswasobservedfor
DOPC/dipalmitoylphosphatidylcholine (DPPC)/cholesterol
as compared with DOPC/DSPC/cholesterol. In both cases,
this tendency was much weaker than that for the DOPC/
SM/cholesterol mixture. This reﬂects the weaker DPPC/cho-
lesterol with respect to SM/cholesterol interactions. Al-
together, it seems that cholesterol clearly interacts more
strongly with sphingolipids than with phospholipids even
for those that are unsaturated [114]. Interestingly, it has
been found that ceramides, generated from SM by the ac-
tion of SMase, displace membrane cholesterol due to a
competition for associating with lipid rafts [115]. Other
GUVs/FCS studies published by Kahya in 2003 [112]p r o v e d
that the lipophilic ﬂuorescent probe DiI-C18 was excluded
from SM enriched regions, while the raft marker GM1 was
present. Furthermore, cholesterol was shown to promote
lipid segregation in DOPC-enriched liquid disordered and
SM-enriched liquid ordered phases. Lipids mobility in SM-
enriched regions signiﬁcantly increased by increasing the
cholesterol concentration.
Another feasible model to explain the generation of lipid
rafts and the diﬀerential cholesterol distribution was pro-
posed by Anderson and Jacobson and is based on pro-
tein/lipid interaction [116]. In this model, also named “the
shell hypothesis,” raft proteins like GPI-anchored proteins
and selected transmembrane and peripheral proteins would
be able to adopt a “shell” formation via interactions with cell
membrane lipids. Caveolins, the proteolipid MAL, ﬂotilins,
and stomatin have been reported to interact with the bi-
layer and have an intimate contact with membrane lipids
forming the so-called “lipid shells,” which are thought to be
thermodynamically stable and diﬀusible unit that coalesce
based on protein-protein interactions. As a result, a larger
functional unit called “lipid raft” would be created. How-
ever, it remains unknown which of the raft proteins are ca-
pable of interacting with lipids in a way to form these lipids
shells.
Pankov et al [117] have hypothesized that integrins, im-
portant protein components of the cholesterol-enriched do-
mains, may have a fundamental role in cholesterol levels and
in the stability of lipid rafts. They demonstrated that integrin
presence in ﬁbroblast plasma membrane increased lipid rafts
cholesterol and sphingomyelin content as well as the nonraft
constituent phosphatidylethanolamine. Even though, they
do not provide details about the mechanism underlying this
fact,alikelyexplanationbasedonphosphatidylethanolamine
thermodynamic incompatibility with cholesterol was pro-
posed.
Rafts and caveolae contain several proteins implicated in
signal transduction pathways [118, 119]. Thus, it is believed
that rafts are implicated directly in transduction events; pos-
sibly allowing a group of proteins to participate in a certain
pathway and isolating others, avoiding the crosstalk of dif-
ferent pathways. They could make the encounter of inter-
acting proteins easier. Rafts are implicated in the integrin
signalling and also in the processing of amyloid precursor
protein (APP) to Aβ [120]. The secretases implicated in the
cleavage of APP are present in rafts, and the processing in Aβ
[121] is dependent on the cholesterol amount in the cell. It
has been proposed that if the cell has more cholesterol, then
ithasmorerafts,allowingtheAPPcleavageandtheposterior
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AMYLOIDPEPTIDE,APP,ANDTHEIRLINKSWITHRAFTS
AND MEMBRANE LIPIDS
By using silver [122] and Congo-red staining [123]i tw a s
possible to see in the tissue aﬀected with Alzheimer’s disease
the lesions produced in the cortical regions of the brain. The
neurons are surrounded by a characteristic large, dark, and
circular inclusion called Alzheimer’s plaque. This plaque is
made of amyloid deposits composed of a peptide of 4kDa
in a β-sheet conformation; this was called β-amyloid [124].
Later, it was discovered that the peptide was part of a 79kDa
protein with 695 amino acids recognized as an amyloid pre-
cursor protein (APP). Hydrophobic analysis of this protein
revealed membrane-spanning segment, a C-terminal cyto-
plasmic domain, and an N-terminal extracellular domain;
it is characterized as a ubiquitously expressed type-1 mem-
brane glycoprotein [125]. APP undergoes alternative splic-
ing originating three varieties depending on the amount
of residues: APP695,A P P 741,A P P 751, and APP770. The two
longer isoforms contain the exon 7, which encodes a serine
protease inhibitor domain. This kind of inhibitors promotes
the outgrowth of neurites providing a possible nonpatholog-
ical function for this protein. The most common isoform
present in the body is APP751, but in the brain, the most
abundant is APP695. APP is widely expressed in cell surface,
especially on neurons, but also in astrocytes, microglia, en-
dothelial cells, smooth muscles, and all peripheral cells.
APP is processed by three enzymes called α, β,a n dγ
secretases. The β-secretase is a member of the ADAM fam-
ily of metalloproteases and the γ-secretase is a membrane-
bound aspartyl protease, also called BACE. These secretases
cleave the ectodomain of APP in diﬀerent sites, resulting in
twofragmentsnamedaftertheinvolvedsecretase:APPsβ and
APPsα. After these cleavages, the α-secretase processes the
transmembrane domain of the APP C-terminal fragments
(α-CTF and β-CTF) producing two smaller fragments called
p3 (for the α previous clip) and Aβ (for the β-clip). The ﬁrst
fragment dissolves easily within the brain, but the second
does not dissolve and therefore it accumulates in the brain,
forming the senile plaques. The Aβ fragments can have 40 or
42 residues (Aβ1−40 or Aβ1−42). The Aβ1−42 is neurotoxic and
more easily aggregates in plaques. Since the fragment pro-
duced by the previous cleavage of the γ-secretase does not
produce Aβ or plaques, it is called “nonamyloidogenic path-
way” and is neuroprotective. This is the major way of APP
metabolism in most cells. Therefore, the stimulation of eas-
ier γ-secretase decreases the Aβ formation and protects from
AD. There are several reagents that can stimulate this secre-
tase, such as estrogen, testosterone, various neurotransmit-
ters, growth factors, and the activation of protein kinase-C
(PKC) by phorbol esters. β-a n dγ-secretases are considered
as participants in the amyloidogenic pathway, especially γ-
secretase because it is associated with presenilins. Two highly
conserved residues in the transmembrane domains 6 and 7
ofpresenilinsseemtobenecessaryforthenormalγ-secretase
activity. Since the presenilin genes PSEN1 and PSEN2 partic-
ipate in familial AD, one possible treatment for the preven-
tion of AD would be the control of γ-secretase activity. Both
β-a n d γ-secretases are present in lipid rafts and these lipid
microdomains containing cholesterol have been implicated
in AD [126]. These membrane domains could function as
a microenvironment, where APP is processed, but while the
generation of Aβ seems to be dependent on rafts and what
occurs there, the processing of the APP by the γ-secretase oc-
curs outside the lipid rafts [120]. The levels of Aβ are not de-
pendent on the cholesterol amount in the cell in vivo [121],
due to cholesterol having no eﬀect over γ-secretase activity,
but the increment in the cholesterol at the membrane can in-
crease the lipid rafts formation and thus allow the APP pro-
cessing by BACE1 (γ-secretase) [126].
OXIDIZED LIPIDS AND CHOLESTEROL IN AD
NeurodegenerativedisorderslikeAlzheimer’sdiseaseencom-
pass oxidative modiﬁcations of lipids and cholesterol de-
tected in serum and cerebrospinal ﬂuid (CSF) of Alzheimer’s
disease patients (AD). The major protein modiﬁcation
by trans-4-hydroxy-2-nonenal (HNE) is the adduction to
lysines, which was observed in postmortem brains of AD
[127, 128]. The neurotoxic eﬀect of HNE, a potent prooxi-
dant, was determined in a cellular culture model. Acrolein is
a more reactive product of the metal-catalyzed oxidation of
polyunsaturated fatty acids [129] detected at increased level
in the brain of AD and becomes neurotoxic to hippocampal
neurons by a calcium-dependent mechanism [130].
Eﬀorts have been made to ﬁnd reliable biological mark-
ers for the initial phase in AD, even before the ﬁrst clinical
evidence for the disease. In this context, the detection of ox-
idative markers such as 4-HNE and 24S-hydroxycholesterol
in plasma and urine samples can help in the early diagnosis
of AD, thus facilitating the treatment approaches.
An elevated level of HNE, produced by the oxidation
of arachidonic acid, was detected in the plasma of AD
[131, 132] malondialdehyde, an end product of lipid per-
oxidation, and was increased in the plasma of AD patients
versus age-matched and nutritionally evaluated control sub-
jects [133]. Nevertheless, malondialdehyde failed as a pre-
dictive AD marker in several other studies [134, 135]. Ele-
vated levels of 24S-hydroxycholesterol, produced via an en-
zymatic oxidation of brain cholesterol by CYP46, were de-
tected in the plasma of AD compared with control age-
matched volunteers [136, 137]. Concomitantly, treatment
with statins lowered the levels of LDL-cholesterol and 24S-
hydroxycholesterol in plasma [138], and it has been sug-
gested that the oxysterol may be an important marker of
AD risk instead of total cholesterol. In summary, 24S-
hydroxycholesterol and HNE are good candidates to be a
marker of AD.
A key role in AD pathology is now assumed to be vas-
cular in origin due to hypoperfusion of microvasculature
that induces hypoxia in brain tissue, events that are associ-
ated with oxidative stress [139]. Moreover, postmortem AD
brains show atherosclerotic hypoperfused microvessels le-
sions that are closely related to oxidative stress markers and
amyloidplaques.Thisscenarioiscompletedbyarecentwork
that has shown an induction of iNOS with a consequent10 Journal of Biomedicine and Biotechnology
peroxynitriteproductioninastrocytecellculturetreatedwith
LDL from AD patients [140], which is in agreement with
an association among lipids/cholesterol, oxidative stress pro-
duction and pathology of AD.
An interesting connection between cholesterol and amyl-
oid-β-peptide (Aβ1−42) has been demonstrated. Aβ:C u 2+
complexes oxidize cholesterol selectively at the C-3 hydroxyl
group, catalytically producing 4-cholesten-3-one and there-
fore mimicking the activity of cholesterol oxidase [141].
Moreover, it was demonstrated that amyloid peptide precur-
sor (APP) protein promotes cholesterol oxidation, yielding
7β-hydroxycholesterol, a proapoptotic oxysterol, but Aβ1−42
was shown to be 200 times more potent as prooxidant
[142, 143].
Sulfatides are a class of sulfated galactocerebrosides that
mediate diverse biological processes including cell growth
regulation,proteintraﬃcking,signaltransduction,adhesion,
neuronal plasticity, and cell morphogenesis which has been
characterized as potential AD marker. A decrease in sulfatide
concentrationinverymilddementiapatientshasbeenfound
[144] but a correlation with Alzheimer’s disease should be
done.
Interestingly, knockout mice for ApoE have between 61–
114% more sulfatides and mice over-expressing ApoE4 ex-
hibit 60% less sulfatides than the “wild type” counterparts.
However, no modiﬁcations in the contents of phospholipids,
sphingolipids, and cholesterol were detected, suggesting a
novel role for ApoE in the brain in mediating sulfatides
metabolism [145].
EXPERIMENTAL MODELS FOR AD AND THE STUDY
OF THE ROLES OF LIPIDS
Studies revealed that an elevated serum cholesterol level is a
risk factor for AD [146]. Based on this epidemiological data,
a wide variety of in vitro and in vivo experimental models
has been used to elucidate potential mechanisms underlying
cholesterol/AD relationships. The involvement of cholesterol
in modulating BACE activity was assessed, and it was ob-
served that cholesterol stimulates the proteolytic activity of
puriﬁed BACE in 100nm unilamellar vesicles [147]. George
etalreportedthatadietwhichinducedhypercholesterolemia
increased APP intracellular domain and reduced soluble Aβ
in the transgenic mouse Tg2576, an AD mouse model that
overexpresses human amyloid β-protein precursor [148].
Even though statins have pleiotropic eﬀects, they have
been widely used to study potential speciﬁc links between
AD and cholesterol in a variety of AD experimental models
[149]. Gender diﬀerences observed in the risk for AD devel-
opment in humans led Park et al to assess the eﬀect of lo-
vastatin in male and female Tg2576 mice separately. Results
showed a reduction of cholesterol levels in both sexes, but
Aβ1−40 peptide levels were increased in female mice only. As
well,nochangeswereobservedintheamountsoffull-length,
α-secretase processed amyloid precursor protein (APP) or
presenilin 1 (PS1) in either sex [150].
Li et al (see [151]) reported that in the transgenic mice
B6Tg2576, an AD mice model that also develops atheroscle-
rosis, there is a positive relationship between the presence
of aortic atherosclerotic lesions and cerebral β-amyloidosis.
Atherogenic diets and spatial learning impairment were also
positively correlated in this model. Cordle and Landreth
demonstrated that statins reduce neuronal Aβ production
and inhibit the microgial mediated inﬂammation by means
of a reduction of isoprenyl intermediates in the cholesterol
biosynthetic pathway [152].
Recently, experiments performed with microglial cul-
tures demonstrated that statins blocks Aβ stimulated phago-
cytosis through inhibition of Rac1. In addition, these exper-
iments paradoxically demonstrated that statins mediate the
inactivation of G-proteins by increasing GTP loading of Rac
and RhoA and by disrupting the interaction of Rac with its
negative regulator RhoGDI [153].
MAIN CURRENT PHARMACOLOGICAL
APPROACHES FOR AD
To understand the therapeutic approaches for AD based
on the changes in lipids metabolism, it is worth to review
the current pharmacological treatments for this disease. The
cholinergic hypothesis of AD is based on the evidence that
cholinergic brain deﬁcits lead to alterations in attention
and memory in animal models, healthy elderly, and cogni-
tively impaired patients. Cholinesterase inhibitors have been
widely accepted by clinical and basic researchers as a piv-
otal part of AD treatment. Furthermore, there is strong ev-
idence supporting the improvement in cognitive and global
function with the use of rivastigmine, donepezil, and galan-
tamine [154]. However, a recent critical analysis of the scien-
tiﬁc evidence has seriously questioned the beneﬁts of these
d r u g si nA D[ 153]. Several studies have established that in
patients who are cognitively impaired, donepezil may delay
the onset of AD [155]. Rivastigmine, which also inhibits bu-
tyrylcholinesterase, has shown beneﬁts in mild to moderate
AD in clinical trials, but side eﬀects at high doses have led
to the suspension of this therapy. A study designed to as-
sess the eﬀects of rivastigmine on the cognitive functioning
of 92 patients suﬀering from dementia with Lewy bodies in-
dicated that rivastigmine produces a signiﬁcant beneﬁt over
placebo on tests of attention, working memory, and episodic
secondary memory [156]. Galantamine, a competitive re-
versible inhibitor of acetylcholesterase and allosteric modu-
latorofnicotinicreceptors,hasshownnogreatcognitionim-
provements in mild to moderate AD, thus galantamine does
not seem to be signiﬁcantly better than donepezil [157].
In addition to its role as an excitatory neurotransmitter,
glutamatecanalsobeneurotoxicinexcessivelevelsleadingto
disproportionate depolarization, inﬂux of calcium into neu-
rons, and cell death. Due to its role in memory impairment
and dementia, glutamate has been considered a potential ag-
gravating factor in AD [159]. On the other hand, three ran-
domized clinical trials have shown that memantine, a gluta-
mate antagonist causes just mild improvements in the cog-
nitive performance of severe AD patients, though side eﬀects
were not very signiﬁcant. Use of memantine has been shown
to slow the decline of the treated patients, rather than causeLeonel Rojo et al 11
Table 2: Summary of the main clinical studies that have provided statins eﬃcacy results in AD or other types of dementias. Dur: duration
of the study (months), N: number of patients, SD: study design, PO: main primary outcomes or biological eﬀects, AO: additional outcomes,
SO: main secondary outcomes, Ref: references.
Drug dosage SD N Dur PO SO AO Results Ref
Diﬀerent statins Case control 284 72 Relative risk of AD
(odd ratio) — — Decrease relative AD risk
(0.29) [56]
Atorvastatin
calcium
80mg/day
Randomized,
double-blind,
placebo-controlled
63 12 ADAS cog and CGIC
change score
ADAS cog,
CGI, and NPI
Scales
—
Improvements in PO,
trends to improving in
SO
[154]
Simvastatin
20mg/day
Uncontrolled,
open trial 19 3
CSF levels of βsAPP, αsAPP,
Tau, phospho-Tau, Aβ1−42,
and plasma levels of Aβ1−42
ADAS cog —
βsAPP, αsAPP decreased,
ADAS-cog slightly
increased
[153]
Simvastatin
20mg/day
Uncontrolled,
open 19 12
CSF levels of Aβ1−42,
βsAPP, αsAPP, totAPP, and
total Tau, plasma levels of
Aβ1−42 ADAS cog
MMSE —
No changes in CSF levels
of Aβ1−42, βsAPP,
totAPP, total Tau,
plasma levels of Aβ1−42,
ADAS cog, and MMSE,
αsAPP increased
[158]
Pravastatin
40mg/day
Randomized,
placebo-controlled 5804 38.4
Coronary death, nonfatal
myocardial infarction, fatal
and nonfatal stroke
— MMSE
No diﬀerences between
treatment and controlled
group
[155]
Simvastatin
40mg/day
Randomized,
placebo-controlled 20.536 60
Plasma levels of LDL, major
coronary events, strokes,
and revascularizations
(separated into prior and
not prior cerebrovascular
disease)
Ischaemic
and/or
hemorrhagic
stroke
(separated
into prior
and not prior
cerebrovascu-
lar
disease)
TICS-m
No diﬀerences in the
cognitive score between
treatment and control
groups
[156]
an actual improvement. Therefore, there seems to be no rea-
son to expect promising results from memantine or better
eﬃcacy than cholinesterase inhibitors [160].
As we previously mentioned, the key event leading to
cognitive impairment in a variety of AD is the formation of
the peptide Aβ1−42, which clusters into amyloid plaques in
brains of patients with AD. β-secretase cleavage followed by
γ-secretase proteolysis are both necessary to cleave APP into
the toxic Aß1−42 [1]. No suﬃciently successful therapeutic
strategies based on the inhibition of both β and γ secretases
have been developed so far. γ-secretase inhibitors are already
being tested in clinical trials, while β-secretase inhibitors are
stillinpreclinicaldevelopment.Otherapproachesincludein-
terfering with the deposition of the Aβ1−42 into plaques and
enhancing its clearance, but none of these approaches has
gained enough scientiﬁc and clinical evidence to support a
feasible therapeutic intervention [161, 162].
It is widely accepted that hyperphosphorylated tau is the
maincomponentofneuroﬁbrillarytangles(NFTs),abroadly
known marker for AD neurodegeneration. Indeed, several
reportspointoutthattauaggregationrequiresananomalous
previous hyperphosphorylation. Both the prolonged activity
of glycogen synthase kinase-3 (GSK3β)a sw e l la sc d k 5 / p 3 5
system deregulation are thought to be pivotal events in tau
hyperphosphorylation [11, 12]. Therapeutic drugs like val-
proic acid and lithium, which are approved for other neuro-
logical and psychiatric disorders, have the ability to inhibit
GSK-3β. However, according to clinical evidences, both the
eﬃcacy and tolerability are limited. Thus, current scientiﬁc
evidence is still too weak to support a feasible pharmacolog-
ical therapeutic avenue for AD [163].
CHOLESTEROL-LOWERING AGENTS (STATINS). ARE
COGNITIVE IMPROVEMENTS THE BOTTLENECK?
Extensive critical revisions of AD treatments have been pub-
lished by a number of authors in recent years [160–162]b u t
none of them puts emphasis on the potential role of statins
in AD based on the existing molecular and clinical evidence.
Here, we have brieﬂy summarized the main current pharma-
cologicaltreatments.Clinicaldataregardingtheuseofstatins
and thier controversial conclusions are also presented in or-
der to overview the problem and analyze its potential impact
on AD treatment (Table 2).12 Journal of Biomedicine and Biotechnology
The epidemiological data regarding the relationship be-
tween the use of statins and the risk of AD is controver-
sial. Most of the preclinical results derived from cells and
animal studies show a direct relationship between elevated
cholesterol levels and molecular or cognitive markers of AD
[15]. However, the current state of research in human stud-
ies is not solid enough to establish a certain and reliable
causal relationship between the use of cholesterol lowering
agents and the incidence of AD and other types of demen-
tias [45, 160, 163, 164]. Concrete clinical evidence has been
provided by Wolozin et al indicating that there is a 60 to 73%
lower prevalence (P<. 001) of probable diagnosed AD in
patients taking lovastatin or pravastatin [165, 166]. Jick et al
reported that patients of 50 years and older had lower risk
of developing dementia, though not speciﬁcally Alzheimer’s,
when treated with statins. This lower relative risk was nei-
ther related to the presence or the absence of hyperlipidemia
[56].
An open uncontrolled clinical trial with the simbas-
tatin in 19 patients with AD settled that 20mg/d of sim-
bastatin for 12 weeks signiﬁcantly reduced the cerebrospinal
ﬂuid (CSF) levels of β-secretase-cleaved amyloid precursor
protein (βsAPP) and α-secretase-cleaved amyloid precursor
protein (αsAPP). Conversely, CSF levels of tau, phospho-
tau, Aβ1−42, and plasma levels of Aβ1−42 remained un-
changed. Cognitive capacity was measured using the dis-
ease assessment scale cognition (ADAS-cog). In this study,
ADAS-cog score was just slightly increased in less than
50% of all patients [167]. Even though, this open ob-
servational study concluded that the simbastatin reduces
Aβ1−42 formation in AD patients, results were not consis-
tent with a cognitive improvement due to the use of simbas-
tatin.
A recently published pilot double-blind, placebo-con-
trolled trial with a one year exposure to atorvastatin calcium
80mg/d in 63 AD patients with an MMSE of 12–28 demon-
strated that atorvastatin produces a signiﬁcant beneﬁcial ef-
fect at 6 months when evaluated using both geriatric depres-
sion scale and the ADAS cog. However, the secondary out-
come measures ADAS cog, CGI, and neuropsychiatric inven-
tory scales, evaluated at 12 months, were not consistent with
certain protection against AD [168].
Another study demonstrated that simbastatin 20mg/d
for 12 months produces no changes in CSF levels of β-
amyloid (Aβ1−42), βsAPP, totAPP, and total tau as com-
pared to the baseline, nor were there changes in Aβ1−42
plasma levels. However, αsAPP was signiﬁcantly increased
suggesting that simbastatin could favor the nonamyloido-
genic APP processing pathway [169]. Studies indicate that
signiﬁcantly more research is needed in order to clar-
ify the roles of cholesterol therapeutic agents in the AD
treatment. At the present stage of this research, there is
cumulative evidence that the search of reliable biomark-
ers for AD, of importance for early AD diagnosis and
monitoring the course of the disease, will allow the
growth of therapeutical approaches, including both phar-
macological treatment and cognitive rehabilitation of pa-
tients.
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